Hansen Medical Inc - Free Writing Prospectus - Filing under Securities Act Rules 163/433 (FWP)
02 4월 2008 - 7:05PM
Edgar (US Regulatory)
|
|
|
|
|
Filed Pursuant to Rule 433
Issuer Free Writing Prospectus dated April 2, 2008
Relating to Prospectus dated March 17, 2008
Registration No. 333-149561
|
Hansen Medical, Inc.
3,000,000 Shares
|
|
|
Issuer:
|
|
Hansen Medical, Inc.
|
Symbol:
|
|
HNSN
|
Shares offered:
|
|
3,000,000 shares
|
Price to public:
|
|
Variable
|
Net Proceeds to the Company:
|
|
Approximately $39.4 million
|
Dilution:
|
|
As of December 31, 2007, the issuer had a per
share net tangible book value of common stock
of $2.23. Based on an assumed public
offering price of $14.58 per share (the last
sale price of our common stock as reported on
The Nasdaq Global Market on April 1, 2008),
if you purchase shares of common stock in
this offering, you will suffer dilution of
approximately $11.04 per share in the net
tangible book value of the common stock and
as a result of the offering, the per share
net tangible book value of common stock will
increase by approximately $1.31.
|
Regulatory:
|
|
Hansen Medical, Inc. (the "Company") is continuously receiving new
information regarding the performance of the
Sensei system during procedures as the number
of procedures using the Sensei system
increases. Consistent with its past
practices, the Company is continually
evaluating events that may require adverse
event reporting to the FDA under its MDR
regulations and anticipates having to do so
in the future. The FDA requires reporting of all
adverse events to the extent that the device
cannot be conclusively ruled out as a
contributing factor. We believe, based on
our analysis of these events to date, that
the MDR reports will not materially impact
our current regulatory status. However, the
FDA may request further information, which
potentially could delay the Companys pending
510(k) application, or which could result in
further regulatory action.
|
Trade date:
|
|
April 1, 2008
|
Closing date:
|
|
April 7, 2008
|
CUSIP:
|
|
411307 10 1
|
|
Underwriter:
|
|
Morgan Stanley & Co. Incorporated
|
We have filed a registration statement (including a prospectus) with the Securities and Exchange
Commission (the SEC) for the offering to which this communication relates. Before you invest,
you should read the prospectus in that registration statement and other documents the issuer has
filed with the SEC for more complete information about the issuer and this offering. You may
obtain these documents for free by visiting EDGAR or the SEC website at www.sec.gov.
Alternatively, a written prospectus and accompanying prospectus supplement related to the offering
may be obtained from Morgan Stanley & Co. Incorporated, 180 Varick Street, New York, New York
10014; Attention: Prospectus Department (telephone: 866.718.1649), or by e-mail at
prospectus@morganstanley.com.
ANY DISCLAIMER OR OTHER NOTICES THAT MAY APPEAR AFTER THIS MESSAGE ARE NOT APPLICABLE TO THIS
COMMUNICATION AND SHOULD BE DISREGARDED. SUCH DISCLAIMERS OR OTHER NOTICES WERE AUTOMATICALLY
GENERATED AS A RESULT OF THIS COMMUNICATION BEING SENT VIA BLOOMBERG OR ANOTHER EMAIL SYSTEM.
Hansen Medical, Inc. (MM) (NASDAQ:HNSN)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Hansen Medical, Inc. (MM) (NASDAQ:HNSN)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024
Hansen Medical, Inc. (MM) (나스닥)의 실시간 뉴스: 최근 기사 0
More Hansen Medical Inc News Articles